Erratum (DOI:10.1016/j.bbmt.2008.12.003);The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 2, 2009, Pages 137-172

  Oliansky, Denise M ^a   Antin, Joseph H ^b   Bennett, John M ^c   Deeg, H Joachim ^d   Engelhardt, Christin ^e   Heptinstall, Kathleen V ^f   de Lima, Marcos ^g   Gore, Steven D ^h   Potts, Ronald G ⁱ   Silverman, Lewis R ^j   Jones, Roy B ^g   McCarthy Jr , Philip L ^a   Hahn, Theresa ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e Aplastic Anemia and MDS International Foundation Inc   (United States)

^f Myelodysplastic Syndromes Foundation   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ INTERLINK Health Services   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Adult; Evidence based review; Hematopoietic stem cell transplantation; Myelodysplastic syndromes; Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AMIFOSTINE; ANTHRACYCLINE; ANTIBIOTIC AGENT; AZACITIDINE; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INFLIXIMAB; INTERLEUKIN 3; IODINE; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DONOR SELECTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

EID: 58249126355     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.03.001     Document Type: Erratum

References (103)

1. Hahn T., Wolff S.N., Czuczman M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 7 (2001) 308-331
2. Hahn T., Wingard J.R., Anderson K.C., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 9 (2003) 4-37
3. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 11 (2005) 823-861
4. Hahn T., Wall D., Camitta B., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 12 (2006) 1-30
5. Oliansky D.M., Rizzo J.D., Aplan P.D., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant 13 (2007) 1-25
6. Oliansky D.M., Appelbaum F., Cassileth P.A., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 14 (2008) 137-180
7. Warlick E.D., O'Donnell P.V., Borowitz M., et al. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res 32 (2008) 1439-1447
8. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
9. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
10. Runde V., de Witte T., Arnold R., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21 (1998) 255-261
11. Oosterveld M., Muus P., Suciu S., et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16 (2002) 1615-1621
12. Nakai K., Kanda Y., Fukuhara S., et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19 (2005) 396-401
13. Scott B.L., Storer B., Loken M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 65-73
14. De Witte T., Zwaan F., Hermans J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 (1990) 151-155
15. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
16. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
17. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
18. Hallemeier C.L., Girgis M.D., Blum W.G., et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 12 (2006) 749-757
19. Nakamura R., Rodriguez R., Palmer J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 40 (2007) 843-850
20. Kroger N., Bornhauser M., Ehninger G., et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82 (2003) 336-342
21. Kroger N., Brand R., van Biezen A., et al. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. Bone Marrow Transplant 35 (2005) 37-43
22. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease Is the strongest factor improving survival. J Clin Oncol 26 (2008) 577-584
23. Sierra J., Perez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
24. Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 (1996) 358-365
25. Wallen H., Gooley T.A., Deeg H.J., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23 (2005) 3439-3446
26. O'Donnell M.R., Long G.D., Parker P.M., et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13 (1995) 2973-2979
27. Lim Z.Y., Ho A.Y., Ingram W., et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135 (2006) 201-209
28. Castro-Malaspina H., Harris R.E., Gajewski J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99 (2002) 1943-1951
29. Arnold R., de Witte T., van Biezen A., et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21 (1998) 1213-1216
30. Anderson J.E., Anasetti C., Appelbaum F.R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93 (1996) 59-67
31. Kernan N.A., Bartsch G., Ash R.C., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328 (1993) 593-602
32. Yakoub-Agha I., de La Salmoniere P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 18 (2000) 963-971
33. Kerbauy D.M.B., Chyou F., Gooley T., et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 11 (2005) 713-720
34. Zang D.Y., Deeg H.J., Gooley T., et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 110 (2000) 217-222
35. Anderson J.E., Appelbaum F.R., and Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 17 (1995) 95-99
36. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993) 677-681
37. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92 (1998) 1910-1917
38. Appelbaum F.R., Barrall J., Storb R., et al. Bone marrow transplantation for patients with myelodysplasia: Pretreatment variables and outcome. Ann Intern Med 112 (1990) 590-597
39. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
40. Kroger N., Zabelina T., Guardiola P., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118 (2002) 67-73
41. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
42. Mattijssen V., Schattenberg A., Schaap N., et al. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 19 (1997) 791-794
43. Oosterveld M., Suciu S., Verhoef G., et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17 (2003) 859-868
44. De Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326-2331
45. De Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000) 620-630
46. De Witte T., Pikkemaat F., Hermans J., et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 15 (2001) 1878-1884
47. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002) 1525-1531
48. Guardiola P., Runde V., Bacigalupo A., et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99 (2002) 4370-4378
49. del Canizo M.C., Martinez C., Conde E., et al. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 32 (2003) 987-992
50. De Witte T., Brand R., van Biezen A., et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 91 (2006) 750-756
51. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
52. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
53. Parker J.E., Shafi T., Pagliuca A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced intensity conditioning compared with standard preparative regimens. Br J Haematol 119 (2002) 144-154
54. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36 (2005) 667-674
55. Solomon S.R., Savani B.N., Childs R., et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 619-626
56. Scott B., Deeg H.J., Storer B., et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 45 (2004) 2409-2417
57. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
58. Anderson J., Appelbaum F., Schoch G., et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87 (1996) 51-58
59. Bennet J., Catovsky D., Daniel M., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
60. Sanz G.F., Sanz M.A., and Greenberg P.L. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83 (1998) 358-368
61. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
62. Germing U., Gattermann N., Strupp C., et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
63. Nosslinger T., Reisner R., Koller E., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 98 (2001) 2935-2941
64. Malcovati L., Porta M.G.D., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
65. Mufti G.J., Stevens J.R., Oscier D.G., et al. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59 (1985) 425-433
66. Worsley A., Oscier D.G., Stevens J., et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 68 (1988) 17-21
67. Sanz G.F., Sanz M.A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989) 395-408
68. Goasguen J., Garand R., Bizet M., et al. Prognostic factors of myelodysplastic syndromes-a simplified 3-D scoring system. Leuk Res 14 (1990) 255-260
69. Aul C., Gattermann N., Heyll A., et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 (1992) 52-59
70. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
71. Morel P., Hebbar M., Lai J.-L., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7 (1993) 1315-1323
72. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
73. Armand P., Kim H.T., Cutler C.S., et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 28-35
74. Kuendgen A., Strupp C., Aivado M., et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 24 (2006) 5358-5365
75. Armand P., Kim H.T., DeAngelo D.J., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13 (2007) 655-664
76. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007) 4246-4254
77. Chang C., Storer B.E., Scott B.L., et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110 (2007) 1379-1387
78. Farag S.S., Elder P.J., Marcucci G., et al. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged > or =50 years compared to younger adults with low-risk disease. Bone Marrow Transplant 31 (2003) 87-93
79. Ballen K.K., Gilliland D.G., Guinan E.C., et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 20 (1997) 737-743
80. Oosterveld M., Wittebol S.H., Lemmens W.A., et al. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 123 (2003) 81-89
81. Stewart B., Verdugo M., Guthrie K.A., et al. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 123 (2003) 879-885
82. Scott B.L., Storer B.E., Greene J.E., et al. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant 13 (2007) 345-354
83. Ross S.D., Allen I.E., Probst C.A., et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 12 (2007) 1264-1273
84. Group ICS. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103 (1998) 1070-1074
85. Thompson J.A., Gilliland D.G., Prchal J.T., et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95 (2000) 1175-1179
86. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104 (2004) 321-327
87. Zwierzina H., Suciu S., Loeffler-Ragg J., et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 19 (2005) 1929-1933
88. Verbeek W., Wormann B., Koch P., et al. Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. J Cancer Res Clin Oncol 125 (1999) 369-374
89. Kantarjian K., Issa J.-P., Rosenfeld C., et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 106 (2006) 1794-1803
90. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
91. Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 (2001) 958-965
92. Strupp C., Germing U., Aivado M., et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16 (2002) 1-6
93. List A., Kurtin S., Roe D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
94. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
95. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111 (2008) 86-93
96. Raza A., Candoni A., Khan U., et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45 (2004) 2099-2104
97. Steensma D.P., Heptinstall K.V., Johnson V.M., et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 32 (2008) 691-698
98. Jansen A.J.G., Essink-Bot M.L., Beckers E.A.M., et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 121 (2003) 270-274
99. Spiriti M., Latagliata R., Niscola P., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromes. Ann Hematol 84 (2005) 167-176
100. Stasi R., Abruzzese E., Lanzetta G., et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005 16 (1921-1927)
101. Kornblith A.B., Herndon II J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J Clin Oncol 20 (2002) 2441-2452
102. Takahashi S., Yamaguchi T., Ooi J., et al. The comparative analysis of bone marrow transplantation and cord blood transplantation from unrelated donors in patients with myelodysplastic syndrome in Japan. [Abstract]. Blood 110 (2007) 2012
103. Passweg J.R., Giagounidis A., Simcock M., et al. Immunosuppression for patients with low and intermediate risk myelodysplastic syndrome: a prospective randomized multicenter trial comparing antithymocyte globulin + cyclosporine with best supportive care: SAKK 33/99. Blood 110 (2007) 1461 [Abstract]